CSPAN2 Key Capitol Hill Hearings February 5, 2016
Efforts in the pharmaceuticals to try to get away from that perception. They have used backlog to capitalize on a system that allows them to pillars of market. Times when there were no backlog and there were still no generic competition to them, other reasons that for a very small segment, the 88 pet for small segments there is no generic competition. She we at the end of the 1st program will have eliminated the backlog and be in a steadystate type of activity, stillactivity, still the problems with drugs that dont have generic competition. Bio similars. Do you think they can play a part in a ...
Source: archive.org
